Characterization of Three CYP2C19 Gene Variants by MassARRAY and Point of Care Techniques: Experience from a Czech Centre

  • Martin Petrek
  • Lenka Kocourkova
  • Veronika Zizkova
  • Zdenek Nosek
  • Milos Taborsky
  • Jana Petrkova
Original Article


Distribution of cytochrome P450 2C19 enzyme gene (CYP2C19) variants affecting metabolism of clopidogrel was determined in 526 Czech patients after percutaneous coronary intervention using MassARRAY genotyping and compared to distribution in other populations of European descent. Fifty-three (10%) patients underwent parallel determination of CYP2C19 genotypes from buccal swabs by a point of care technique with 100% concordance to the main genotyping platform. Observed CYP2C19 genotypes were related to clopidogrel metabolism phenotypes and discussed in population context. Hereby, presented methodologies provide accurate CYP2C19 genotyping results in a relatively short time of one up to 12 h and may, therefore, find the relevant place in the field of genotype-guided antiplatelet therapy.


CYP2C19 Pharmacogenetics Clopidogrel Genotyping Point of care 



Part of this work was performed when Laboratory of Cardiogenomics was affiliated to the Department of Clinical and Molecular Pathology, University Hospital Olomouc. This work was partially supported by Grants: IGA PU: LF_2013_009, 2014_012, 2015_020, and LO1304.


  1. Beitelshees AL (2012) Personalised antiplatelet treatment: a RAPIDly moving target. Lancet 379:1680–1682CrossRefPubMedGoogle Scholar
  2. Beitelshees AL, Voora D, Lewis JP (2015) Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics. Pharmgenom Pers Med 8:43–61Google Scholar
  3. Chae H, Kim M, Koh YS et al (2013) Feasibility of a microarray-based point-of-care CYP2C19 genotyping test for predicting clopidogrel on-treatment platelet reactivity. Biomed Res Int 2013:154073CrossRefPubMedPubMedCentralGoogle Scholar
  4. Desai NR, Canestaro WJ, Kyrychenko P et al (2013) Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention. Circ Cardiovasc Qual Outcomes 6:694–699CrossRefPubMedGoogle Scholar
  5. Haselmann V, Geilenkeuser WJ, Helfert S (2016) Thirteen years of an international external quality assessment scheme for genotyping: results and recommendations. Clin Chem 62:1084–1095CrossRefPubMedGoogle Scholar
  6. Hulot JS, Collet JP, Silvain J et al (2010) Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 56:134–143CrossRefPubMedGoogle Scholar
  7. Jani M, Barton A, Ho P (2015) Pharmacogenetics of treatment response in psoriatic arthritis. Curr Rheumatol Rep 17(7):44. doi: 10.1007/s11926-015-0518-z CrossRefPubMedPubMedCentralGoogle Scholar
  8. Jiang M, You JH (2015) Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy. Expert Opin Pharmacother 16:771–779CrossRefPubMedGoogle Scholar
  9. Kazi DS, Garber AM, Shah RU et al (2014) Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. Ann Intern Med 160:221–232CrossRefPubMedGoogle Scholar
  10. Kishore A, Žižková V, Kocourková L et al (2015) A dataset of 26 candidate gene and pro-inflammatory cytokine variants for association studies in idiopathic pulmonary fibrosis: frequency distribution in normal Czech population. Front Immunol 22:476Google Scholar
  11. Kishore A, Žižková V, Kocourková L et al (2016) Association study for 26 candidate loci in idiopathic pulmonary fibrosis patients from four European populations. Front Immunol 7:274PubMedPubMedCentralGoogle Scholar
  12. Knauer MJ, Diamandis EP, Hulot JS et al (2015) Clopidogrel and CYP2C19: pharmacogenetic testing ready for clinical prime time? Clin Chem 61:1235–1240CrossRefPubMedGoogle Scholar
  13. Li Y, Tang HL, Hu YF et al (2012) The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. J Thromb Haemost 10:199–206CrossRefPubMedGoogle Scholar
  14. Lin G, Yi L, Zhang K et al (2015) Implementation of cell samples as controls in national proficiency testing for clopidogrel therapy-related CYP2C19 genotyping in China: a novel approach. PLoS One 10:e0134174CrossRefPubMedPubMedCentralGoogle Scholar
  15. Marziliano N, Notarangelo MF, Cereda M et al (2015) Rapid and portable, lab-on-chip, point-of-care genotyping for evaluating clopidogrel metabolism. Clin Chim Acta 451:240–246CrossRefPubMedGoogle Scholar
  16. Mega JL, Close SL, Wiviott SD et al (2010a) Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 376:1312–1319CrossRefPubMedPubMedCentralGoogle Scholar
  17. Mega JL, Simon T, Collet JP et al (2010b) Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304:1821–1830CrossRefPubMedPubMedCentralGoogle Scholar
  18. Ortega VE, Meyers DA, Bleecker ER (2015) Asthma pharmacogenetics and the development of genetic profiles for personalized medicine. Pharmgenom Pers Med 8:9–22Google Scholar
  19. Pedersen RS, Brasch-Andersen C, Sim SC et al (2010) Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. Eur J Clin Pharmacol 66:1199–1205CrossRefPubMedGoogle Scholar
  20. Petrek M (2015) Personalized medicine in sarcoidosis: predict responders and nonresponders. Curr Opin Pulm Med 21:532–537CrossRefPubMedGoogle Scholar
  21. Ragia G, Arvanitidis KI, Tavridou A et al (2009) Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece. Pharmacogenomics 10:43–49CrossRefPubMedGoogle Scholar
  22. Roberts JD, Wells GA, LeMay MR et al (2012) Point-of-care genetic testing for personalization of antiplatelet treatment (rapid gene): a prospective, randomised, proof of concept trials. Lancet 379:1705–1711CrossRefPubMedGoogle Scholar
  23. Scott SA, Sangkuhl K, Stein CM et al (2013) Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 94:317–323CrossRefPubMedPubMedCentralGoogle Scholar
  24. So DY, Wells GA, McPherson R et al (2016) A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study. Pharmacogenom J 16:71–78CrossRefGoogle Scholar
  25. Sofi F, Giusti B, Marcucci R et al (2011) Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J 11:199–206CrossRefPubMedGoogle Scholar
  26. Stacey G, Ziaugra L, Tabbaa D (2009) SNP genotyping using the sequenom MassARRAY iPLEX platform. Curr Protoc Hum Genet 60:2.12.1–2.12.18Google Scholar
  27. Tangamornsuksan W, Lohitnavy O, Kongkaew C et al (2015) Association of HLA-B*5701 genotypes and abacavir-induced hypersensitivity reaction: a systematic review and meta-analysis. J Pharm Pharm Sci 18:68–76CrossRefPubMedGoogle Scholar
  28. The 1000 Genomes Project Consortium (2015) A global reference for human genetic variation. Nature 526:68–74CrossRefPubMedCentralGoogle Scholar
  29. US Food and Drug Administration (2010) FDA drug safety communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug (online). Accessed 25 July 2016
  30. Yip V, Hawcutt DB, Pirmohamed M (2015) Pharmacogenetic markers of drug efficacy and toxicity. Clin Pharmacol Ther 98:61–70CrossRefPubMedGoogle Scholar
  31. Zabalza M, Subirana I, Sala J et al (2012) Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart 98:100–108CrossRefPubMedGoogle Scholar

Copyright information

© L. Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland 2016

Authors and Affiliations

  1. 1.Laboratory of Cardiogenomics-LEMUniversity Hospital OlomoucOlomoucCzech Republic
  2. 2.Faculty of Medicine and Dentistry, Institute of Molecular and Translational MedicinePalacký University OlomoucOlomoucCzech Republic
  3. 3.Department of Pathological Physiology, Faculty of Medicine and DentistryPalacký University OlomoucOlomoucCzech Republic
  4. 4.Department of Internal Medicine-Cardiology, Faculty of Medicine and DentistryPalacký University and University Hospital OlomoucOlomoucCzech Republic

Personalised recommendations